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Introduction:  COPD exacerbations are associated with worsening symptoms including cough, shortness 
of breath, sputum production and worsening airflow obstruction. Increased number of exacerbations is 
associated with morbidity and mortality (1). Exacerbations are classically believed to be associated with 
viral or bacterial infection, although they may also be associated with non-infectious stimuli including 
eosinophilic inflammation or pauci-granulocytic exacerbation such as the worsening of cardiovascular 
disease (2). The mainstay treatment for exacerbation of COPD is antibiotics and corticosteroids, 
however treatment with these is not always successful and there is a need for more personalised 
management of exacerbations (3).  
One of the largest studies of the sputum microbiome in COPD compared the microbiome at stability and 
exacerbation in 161 exacerbations in 78 patients and found no consistent changes in the microbiome 
with no overall difference in Shannon diversity index between the groups (4). The most striking finding 
of this study was that COPD exacerbations could be classified into bacterial, viral and eosinophilic and 
patients showed remarkable consistency of their exacerbation phenotype over time. A number of 
studies have previously supported these defined phenotypes of exacerbation in COPD (2).  
We therefore aimed in this study to examine whether we could observe changes in the microbiome 
from stability to COPD exacerbation within these 3 subtypes of clinically defined events. 
Methods:  Patients were invited to participate in the study and were included if they were >40 years, 
had a FEV1/FVC ratio <70% at screening, and a clinical diagnosis of COPD.  Exclusion criteria included the 
inability to give informed consent; primary diagnosis of asthma; and systemic immunosuppression 
(excluding prednisolone at 5mg or less daily). Patients were required to be clinically stable and 4 weeks 
free from antibiotic or corticosteroid treatment at baseline for enrolment. Patients provided an induced 
sputum sample at baseline and attended for a further induced sputum sample at exacerbation if one 
occurred within 6 months. Details of this cohort have been previously reported.(5) Exacerbations were 
classified as bacterial (positive sputum culture), eosinophilic or viral/paucigranulocytic as previously 
described (2, 4). Bacterial/viral co-infections were analysed as bacterial for the purposes of this analysis. 
DNA was extracted from sputum followed by 16S rRNA gene sequencing on the Illumina MiSeq platform.  
Bioinformatic analysis and quality checking of the resulting sequences was performed using QIIME 
(version 1.9.0). Appropriate negative (water) extraction and sequencing controls were included.  
Shannon-Wiener Diversity Index (SWDI) was used as a measure of alpha diversity within samples. Beta-
diversity was analysed using principle coordinates analysis and groups were compared using 
Permutational multivariate analysis of variance based on the Bray Curtis similarity index. Differences 
between two groups were further evaluated using Linear discriminant analysis Effect Size (LEfSe) with 
false discovery rate (FDA) adjustment for multiple testing. Paired tests were used when comparing 
paired stable and exacerbation samples, while exacerbation subgroups were analysed as independent 
groups. Detailed methods have been previously described (5) and all sequences generated are available 
in the NCBI Sequence Read Archive under the Bioproject accession numbers PRJNA539959 and 
PRJNA316126. 
Results: We studied 46 participants who experienced a total of 73 exacerbations. Mean age 70.8 years 
(standard deviation ±7.0), 27 male (58.7%), 69.6% were receiving inhaled corticosteroids, mean BMI 
27.3 (SD ±4.8), Mean MRC dyspnoea score 2.9 (SD ±1.3). The mean FEV1 was 1.45L (SD ±0.54) equating 
to 63.3% predicted (SD ±22). Mean baseline SGRQ total score was 40.3 (SD ±26.6) and CAT score was 
17.2 (10.7). Using the GOLD classification system 5 participants were GOLD A, 5 were GOLD B, 2 were 
GOLD C and 34 were classified as GOLD D.  
Using the exacerbation endotype classification, 33 exacerbations were bacterial, 19 eosinophilic and 21 
viral. For bacterial events the most frequently identified bacteria was Haemophilus influenzae in 54.5% 
of cases, followed by Moraxella catarrhalis (27.2%). Pseudomonas aeruginosa was identified in 3 cases 
(9.1%).  
Visualising stable and exacerbation samples by principle coordinate analysis there was no obvious 
clustering of stable and exacerbation samples (figure 1A). Consistent with this observation there were 
no significant differences between groups by PERMANOVA (p=0.08). LEfSe identified reduced levels of 
Megasphaera (LDA score 2.1, FDR adjusted P value 0.014), Leptotrichia (LDA score 2.22, FDR adjusted p-
value 0.043), Veillonella (LDA score 3.32, FDR adjusted p-value=0.043 and Campylobacter (LDA score 
2.0, FDR adjusted p-value 0.043) at exacerbation. Prevotella was not significantly different after FDR 
adjustment (LDA score 2.78, p=0.059) (figure 1B). ).  ICS use was not found to be associated with 
microbiome composition, in terms of either alpha-diversity (p=0.77) or beta-diversity (p=0.86). 
We conclude there are no large differences between stable disease and exacerbation at the overall 
community level. We therefore evaluated whether there were differences between exacerbation 
endotypes. Classifying exacerbations as bacterial, eosinophilic or viral/other resulted in significant 
differences by PERMANOVA, p=0.003 (figure 1C). Differences in alpha-diversity were observed across 
the 3 exacerbation groups (ANOVA, p=0.0005) with a lower Shannon-wiener diversity index particularly 
in the bacterial exacerbation group (t-test, p=0.0003). There was no significant difference in Shannon 
diversity index between stable and exacerbation for the other groups (p=0.66 for eosinophilic and 
p=0.053 for viral/other by paired t tests). Similar results were observed with different alpha-diversity 
metrics, with between group differences in Chao index (p=0.019) and Simpsons index (p=0.0024) with 
lower diversity again demonstrated in those exacerbations associated with positive bacterial culture.  
Higher CAT scores indicate more severe symptoms during exacerbations. The mean CAT scores for the 3 
exacerbation subtypes were bacterial 24.2 (SD ±6.7), eosinophilic 17.6 (SD ±8.5), viral/other 21.1 (SD 
±7.0). The difference between bacterial and eosinophilic was statistically significant (t-test, p=0.0067). 
Discussion: Our analysis demonstrates that subgrouping exacerbations into bacterial, eosinophilic and 
viral/other endotypes results in significant differences in microbiome composition and identifies more 
symptomatic exacerbations as measured by the COPD assessment test. We found, as reported by 
others, that there are no significant difference between stable and exacerbation microbiome profiles as 
a whole (6-8). This adds to the growing literature suggesting that COPD exacerbations are 
heterogeneous events with diverse aetiologies and likely to require different treatments (9). LEfse 
shows that the taxa associated with a stable or less severe microbiome, which are predominantly oral 
taxa, constitute the largest change across the whole of the group. This suggests that a loss of these 
organisms, as opposed to increases of traditionally regarded pathogenic taxa like Haemophilus or 
Pseudomonas is the most common change observed at exacerbation. This is highly consistent with the 
findings from AERIS where no consistent changes in Haemophilus or Streptococcus were observed 
comparing stability to exacerbation [4].  
We show bacterial events are associated with a significant loss of diversity and divergent changes in the 
overall composition of the microbiome, unlike subjects in the ‘eosinophilic exacerbation’ endotype who 
do not experience significant changes in microbiome composition. Additionally, higher CAT scores were 
observed in the bacterial exacerbation subgroup overall and were significantly different from the 
eosinophilic subgroup.  This seems to confirm that bacterial and eosinophilic exacerbations are different 
and underscores the importance of a personalised approach to treatment.  
A limitation of this study was the relatively small sample size (n=46), however the results were 
concordant with the larger AERIS study (n=78) and COPD-MAP cohort (4, 6). In particular COPD-MAP 
using different analysis methods identified a reduction in Veillonella at exacerbation which replicated 
here (6). As this was a study that included patients experiencing an exacerbation, there was a certain 
bias towards GOLD D patients and so may be reflective of a more severe COPD population than other 
studies. We allowed up to 2 exacerbations per patient, which may introduce bias but analysis limited to 
one exacerbation per subject produced similar results (not shown). Although 16s rRNA sequencing is a 
powerful tool in providing a comprehensive description of the lung microbiome, it does have certain 
limitations, including bias towards certain bacterial taxa, exclusion of mycobacteria and viruses, and risk 
of contamination (6). This study used sputum, which are typically high biomass samples and included 
appropriate negative controls to minimise contamination risk. Nevertheless sputum is regarded as an 
intermediate sample between the upper and lower airway microbiome and so different results may be 
seen with studies utilising bronchoalveolar lavage (10).   
Taken together, recent 16s rRNA sequencing data highlight the importance of phenotyping and 
endotyping exacerbations. Although the microbiome is not currently an easily accessible technology for 
clinical practice, our analysis demonstrates that using easily available biomarkers like bacterial culture or 
potentially a rapid PCR test for pathogens, blood eosinophils or biomarker surrogates may be practical 
options and may allow more personalized treatment of exacerbations.   
 
 
1. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to 
exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010 Sep 16;363(12):1128-38. 
2. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic 
obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit 
Care Med. 2011 Sep 15;184(6):662-71. 
3. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the 
Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science 
committee report 2019. Eur Respir J. 2019 May;53(5). 
4. Mayhew D, Devos N, Lambert C, Brown JR, Clarke SC, Kim VL, et al. Longitudinal profiling of the 
lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD 
exacerbations. Thorax. 2018 May;73(5):422-30. 
5. Dicker AJ, Crichton ML, Pumphrey EG, Cassidy AJ, Suarez-Cuartin G, Sibila O, et al. Neutrophil 
extracellular traps are associated with disease severity and microbiota diversity in patients with chronic 
obstructive pulmonary disease. J Allergy Clin Immunol. 2018 Jan;141(1):117-27. 
6. Wang Z, Singh R, Miller BE, Tal-Singer R, Van Horn S, Tomsho L, et al. Sputum microbiome 
temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of 
the COPDMAP study. Thorax. 2018 Apr;73(4):331-8. 
7. Ghebre MA, Pang PH, Diver S, Desai D, Bafadhel M, Haldar K, et al. Biological exacerbation 
clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator 
and microbiome profiles. J Allergy Clin Immunol. 2018 Jun;141(6):2027-36 e12. 
8. Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller BE, et al. Lung microbiome dynamics 
in COPD exacerbations. Eur Respir J. 2016 Apr;47(4):1082-92. 
9. Alotaibi NM, Chen V, Hollander Z, Hague CJ, Murphy DT, Leipsic JA, et al. Phenotyping COPD 
exacerbations using imaging and blood-based biomarkers. Int J Chron Obstruct Pulmon Dis. 
2018;13:217-29. 
10. Sulaiman I, Wu BG, Li Y, Scott AS, Malecha P, Scaglione B, et al. Evaluation of the airway 
microbiome in nontuberculous mycobacteria disease. Eur Respir J. 2018 Oct;52(4). 
11. Knight R, Vrbanac A, Taylor BC, Aksenov A, Callewaert C, Debelius J, et al. Best practices for 





Figure 1. A: PCoA showing clustering of stable and exacerbation samples in the study. No differences 
were observed by PERMANOVA between the two groups (p=0.075). B: Linear discriminant analysis Effect 
Size. Features with an LDA score greater than 1 are shown. Those that reach statistical significance after 
FDR adjustment are described in the text. Blue indicates taxa that are more abundant in stable samples 
while red indicates samples more abundant in exacerbation samples. C: PCoA as in (A) but with samples 
labelled 0-3 where 0= stable, 1=bacterial exacerbation, 2=eosinophilic exacerbation 3= Viral 
exacerbation or unexplained exacerbation. The ellipses are coloured according to group. The differences 
between exacerbation groups were statistically significant by PERMANOVA (p=0.003). D: Differences 
between stable and exacerbation subgroups using the Shannon diversity index as an alpha-diversity 
metric. E: Mean CAT scores for each subgroup of exacerbation, 1=bacterial, 2=eosinophilic, 3=viral 
(p=0.0067). 
 
